Gefitinib and Epidermal Growth Factor Receptor Gene Copy Number Aberrations in Esophageal Cancer
Purpose: The cancer esophagus gefitinib (COG) trial demonstrated improved progression free survival with the Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI), gefitinib relative to placebo in advanced esophageal cancer patients with disease progression after chemotherapy. Rapi...
| Main Authors: | , , , , |
|---|---|
| Formato: | Journal article |
| Publicado em: |
American Society of Clinical Oncology
2017
|
| _version_ | 1826283539856883712 |
|---|---|
| author | Petty, R Dahle-Smith, A Stevenson, D Dutton, S Roberts, C |
| author_facet | Petty, R Dahle-Smith, A Stevenson, D Dutton, S Roberts, C |
| author_sort | Petty, R |
| collection | OXFORD |
| description | Purpose: The cancer esophagus gefitinib (COG) trial demonstrated improved progression free survival with the Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI), gefitinib relative to placebo in advanced esophageal cancer patients with disease progression after chemotherapy. Rapid and durable responses were observed in a minority. We hypothesised that genetic aberration of the EGFR pathway would identify patients benefitting from gefitinib. <br/><br/> Patients and Methods: A pre-specified blinded molecular analysis of COG trial tumours was conducted to compare efficacy of gefitinib to placebo according to EGFR copy number gain (CNG) and EGFR, KRAS, BRAF and PIK3CA mutation status. EGFR CNG was determined by fluorescent insitu hybridisation (FISH) using pre-specified criteria and EGFR FISH positive defined as high polysomy or amplification. <br/><br/> Results: Biomarker data were available for 340 patients. In EGFR FISH positive tumours (20.2%) overall survival was improved with gefitinib compared to placebo (hazard ratio [HR] for death, 0.59; 95% confidence interval [CI], 0.35, 1.00 p=0.05). In EGFR FISH negative tumours there was no difference in overall survival with gefitinib compared to placebo (HR for death, 0.90, 95% CI 0.69, 1.18 p=0.46). EGFR amplification (7.2%) patients gained greatest benefit from gefitinib (HR for death, 0.21; 95% CI 0.07-0.64; p=0.006). There was no difference in overall survival for gefitinib versus placebo for patients with EGFR, KRAS, BRAF and PIK3CA mutations, or for any mutation versus none. <br/><br/> Conclusion: EGFR CNG assessed by FISH appears to identify a subgroup of esophageal cancer patients who may benefit from gefitinib as a second line treatment, and suggests that anti-EGFR 3 therapies should be investigated in prospective clinical trials in different settings in EGFR FI SH positive, and in particular EGFR amplified, esophageal cancer. |
| first_indexed | 2024-03-07T01:00:24Z |
| format | Journal article |
| id | oxford-uuid:8983c31d-8bc0-43a4-a5dd-3962c6c478ed |
| institution | University of Oxford |
| last_indexed | 2024-03-07T01:00:24Z |
| publishDate | 2017 |
| publisher | American Society of Clinical Oncology |
| record_format | dspace |
| spelling | oxford-uuid:8983c31d-8bc0-43a4-a5dd-3962c6c478ed2022-03-26T22:25:10ZGefitinib and Epidermal Growth Factor Receptor Gene Copy Number Aberrations in Esophageal CancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8983c31d-8bc0-43a4-a5dd-3962c6c478edSymplectic Elements at OxfordAmerican Society of Clinical Oncology2017Petty, RDahle-Smith, AStevenson, DDutton, SRoberts, CPurpose: The cancer esophagus gefitinib (COG) trial demonstrated improved progression free survival with the Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI), gefitinib relative to placebo in advanced esophageal cancer patients with disease progression after chemotherapy. Rapid and durable responses were observed in a minority. We hypothesised that genetic aberration of the EGFR pathway would identify patients benefitting from gefitinib. <br/><br/> Patients and Methods: A pre-specified blinded molecular analysis of COG trial tumours was conducted to compare efficacy of gefitinib to placebo according to EGFR copy number gain (CNG) and EGFR, KRAS, BRAF and PIK3CA mutation status. EGFR CNG was determined by fluorescent insitu hybridisation (FISH) using pre-specified criteria and EGFR FISH positive defined as high polysomy or amplification. <br/><br/> Results: Biomarker data were available for 340 patients. In EGFR FISH positive tumours (20.2%) overall survival was improved with gefitinib compared to placebo (hazard ratio [HR] for death, 0.59; 95% confidence interval [CI], 0.35, 1.00 p=0.05). In EGFR FISH negative tumours there was no difference in overall survival with gefitinib compared to placebo (HR for death, 0.90, 95% CI 0.69, 1.18 p=0.46). EGFR amplification (7.2%) patients gained greatest benefit from gefitinib (HR for death, 0.21; 95% CI 0.07-0.64; p=0.006). There was no difference in overall survival for gefitinib versus placebo for patients with EGFR, KRAS, BRAF and PIK3CA mutations, or for any mutation versus none. <br/><br/> Conclusion: EGFR CNG assessed by FISH appears to identify a subgroup of esophageal cancer patients who may benefit from gefitinib as a second line treatment, and suggests that anti-EGFR 3 therapies should be investigated in prospective clinical trials in different settings in EGFR FI SH positive, and in particular EGFR amplified, esophageal cancer. |
| spellingShingle | Petty, R Dahle-Smith, A Stevenson, D Dutton, S Roberts, C Gefitinib and Epidermal Growth Factor Receptor Gene Copy Number Aberrations in Esophageal Cancer |
| title | Gefitinib and Epidermal Growth Factor Receptor Gene Copy Number Aberrations in Esophageal Cancer |
| title_full | Gefitinib and Epidermal Growth Factor Receptor Gene Copy Number Aberrations in Esophageal Cancer |
| title_fullStr | Gefitinib and Epidermal Growth Factor Receptor Gene Copy Number Aberrations in Esophageal Cancer |
| title_full_unstemmed | Gefitinib and Epidermal Growth Factor Receptor Gene Copy Number Aberrations in Esophageal Cancer |
| title_short | Gefitinib and Epidermal Growth Factor Receptor Gene Copy Number Aberrations in Esophageal Cancer |
| title_sort | gefitinib and epidermal growth factor receptor gene copy number aberrations in esophageal cancer |
| work_keys_str_mv | AT pettyr gefitinibandepidermalgrowthfactorreceptorgenecopynumberaberrationsinesophagealcancer AT dahlesmitha gefitinibandepidermalgrowthfactorreceptorgenecopynumberaberrationsinesophagealcancer AT stevensond gefitinibandepidermalgrowthfactorreceptorgenecopynumberaberrationsinesophagealcancer AT duttons gefitinibandepidermalgrowthfactorreceptorgenecopynumberaberrationsinesophagealcancer AT robertsc gefitinibandepidermalgrowthfactorreceptorgenecopynumberaberrationsinesophagealcancer |